Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03893487 · ClinicalTrials.gov registry record · Early Phase 1
Fimepinostat in Treating Brain Tumors in Children and Young Adults
A Early Phase 1 study of Recurrent Glioblastoma and Diffuse Intrinsic Pontine Glioma, sponsored by Sabine Mueller, MD, PhD.
- Active
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 19
- Study locations
NCT03893487 is a Early Phase 1 study of Recurrent Glioblastoma and Diffuse Intrinsic Pontine Glioma that is active but no longer recruiting, run by Sabine Mueller, MD, PhD. The registered enrollment target is 30 participants, below the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (56% lower). The trial reports 19 study locations across 17 states.
The verdict
NCT03893487, a Early Phase 1 study of Recurrent Glioblastoma and Diffuse Intrinsic Pontine Glioma, is active but no longer recruiting, sponsored by Sabine Mueller, MD, PhD.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 19
- Study locations
Study Summary
This trial studies how well fimepinostat works in treating patients with newly diagnosed diffuse intrinsic pontine glioma, or medulloblastoma, or high-grade glioma that have come back. Fimepinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- PROCEDURE Therapeutic Conventional Surgery
- DRUG Fimepinostat
Study Locations (19)
California
- Children's Hospital Los Angeles (CHLA) - Los Angeles
- Rady Children's Hospital - San Diego
- University of California, San Francisco - San Francisco
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- University of Florida - Gainesville
Illinois
- Lurie Children's Hospital of Chicago - Chicago
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan Hospital - Ann Arbor
Minnesota
- Children's Minnesota Research Institute - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-08-07 |
| Est. Completion | 2027-08-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03893487
The ClinicalTrials.gov registry entry for NCT03893487 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (56% lower). The listed sponsor is Sabine Mueller, MD, PhD, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Therapeutic Conventional Surgery is the first listed.
NCT03893487 reports 19 study locations spanning 17 distinct geographic areas - top geographies include California, District of Columbia, Florida.
Frequently Asked Questions
What is clinical trial NCT03893487 about?
NCT03893487 is a clinical study titled "Fimepinostat in Treating Brain Tumors in Children and Young Adults". This trial studies how well fimepinostat works in treating patients with newly diagnosed diffuse intrinsic pontine glioma, or medulloblastoma, or high-grade glioma that have come back. Fimepinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT03893487?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2019-08-07. Estimated completion is 2027-08-31.
What conditions does trial NCT03893487 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma, Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Anaplastic Astrocytoma.
What interventions are being tested in trial NCT03893487?
The interventions under investigation include: Therapeutic Conventional Surgery (PROCEDURE), Fimepinostat (DRUG).
Who is sponsoring clinical trial NCT03893487?
This trial is sponsored by Sabine Mueller, MD, PhD, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03893487 being conducted?
This trial has 19 study locations across California, District of Columbia, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma
RECRUITING · Early Phase 1
-
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
RECRUITING · Early Phase 1
-
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
RECRUITING · Early Phase 1
-
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Natural Progesterone for the Treatment of Recurrent Glioblastoma
ACTIVE NOT RECRUITING · Early Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.